IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4316
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$7M
Stephan Jackman
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative diseases and psychiatric disorders. The company was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ALZN Alzamend Neuro, Inc. | 33 | 19 | 1 | 56 | 5.9x | - | 24.3% | 20.5% | - | - | - | - | 0.0% | 18.0x | $7M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
Alzamend Neuro, Inc. (ALZN) receives a "Avoid" rating with a composite score of 32.7/100. It ranks #4316 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
In-line with peers — no strong momentum signal
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for ALZN.
View All RatingsROE proxy 24.3% (sector -1.9%)
GM N/A vs sector 44%, OM N/A vs sector 3%
Capital turnover N/A
Rev growth N/A, 6yr history
Interest coverage -1087.5x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate Alzamend Neuro, Inc. (ALZN) as Avoid with a composite score of 32.7/100 at a current price of $2.10. The stock falls in the bottom quintile, and the multi-factor weakness suggests a high probability of continued underperformance.
Alzamend Neuro, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 32.7/100 places it at rank #4316 in our full universe.
No Moat
High
Exemplary
Fair Value
Returns on equity of 24.3% exceed cost of capital.
Stable competitive position in a defensive sector.
Below-average quality raises earnings sustainability concerns.
Vulnerability to macroeconomic shocks and interest rate volatility.
Alzamend Neuro, Inc. represents a avoid based on multi-factor quantitative performance.
Our quantitative model flags Alzamend Neuro, Inc. with an Avoid rating, assigning a composite score of 32.7/100 and 1 out of 5 stars. Ranked #4316 of 7,333 stocks, ALZN falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
Alzamend Neuro, Inc. registers a weak quality score of just 19/100, indicating significant profitability challenges. The company reports a return on equity of 24.3% (sector avg: -1.9%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.
ALZN registers a value score of just 1/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/E ratio of 5.94x, a P/B ratio of 1.44x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
Alzamend Neuro, Inc.'s investment score of 24/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of 20.5% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
ALZN demonstrates moderate momentum with a score of 56/100, suggesting a neutral price trend without strong directional conviction. Revenue growth data is not currently available, while a beta of 6.34 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
Alzamend Neuro, Inc. registers a low stability score of 14/100, indicating high volatility and potentially stressed financial conditions. Key stability metrics include a beta of 6.34 and a debt-to-equity ratio of 18.00x (sector avg: 0.2x). Stocks at this level carry elevated capital loss risk and may be unsuitable for conservative portfolios without careful risk management.
ALZN carries a short interest score of 71/100, indicating moderate short selling activity. This is a neutral reading — not enough to signal systemic bearishness, but worth monitoring. Specific risk factors include high market sensitivity (beta: 6.34), elevated leverage (D/E: 18.00x), micro-cap liquidity risk. At $7M market cap (micro-cap), Alzamend Neuro, Inc. offers reasonable institutional liquidity.
Alzamend Neuro, Inc. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4316 of 7,333 overall (41st percentile). Key comparisons include ROE of 24.3% exceeding the -1.9% sector median. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While ALZN currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Value (1) would have the largest impact on the composite score.
ROE 1379% BELOW SECTOR MEDIAN
Debt/Equity 8471% ABOVE SECTOR MEDIAN
Div. Yield NaN% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
Shares of American Eagle Outfitters, Inc. (NYSE: AEO) declined during Tuesday’s session after the company reported third-quarter financial results. Net revenue rose 5% Y/Y to $1.30 billion, beating the consensus of $1.28 billion. EPS of $0.49 surpassed the consensus of $0.48. For FY23, AEO revised guidance for revenue to be up mid-single digits Y/Y from growth in low single digits Y/Y earlier. American Eagle fell 16.4% to $16.52 on Tuesday. Here are some other stocks moving in today's mid-day session. Gainers Safe and Green Development Corporation (NASDAQ: SGD) shares gained 66% to $4.7119. Safe and Green Development unveiled a Letter of Intent for integration of real estate AI software. Mountain Crest Acquisition Corp. IV (NASDAQ: MCAF) shares jumped 52.4% to $9.92 after falling more than 12% on Monday. Anghami Inc. (NASDAQ: ANGH) shares jumped 36% to $2.1488. OSN Group announced up to $50 million cash investment in Anghami. TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) shares gained 27.9% to $0.2219. TRACON Pharmaceuticals recently announced license of product development platform for $3 million upfront payment. Marpai, Inc. (NASDAQ: MRAI) rose 24.2% to $1.1301. Marpai Form 4 filing showed Eitan Yaron bought 100,000 shares at an average price of $1.23 per share. Symbotic Inc. (NASDAQ: SYM) jumped 23.8% to $46.02 after the company reported better-than-expected fourth-quarter sales results. Burlington Stores, Inc. (NYSE: BURL) gained 19% to $162.77 after the company reported third-quarter financial results and issued guidance. Hibbett, Inc. (NASDAQ: HIBB) jumped 14.7% to $61.55 following strong quarterly sales. LQR House Inc. (NASDAQ: LQR) shares surged 14.5% to $0.0691. LQR House repurchased 1,476,355 shares in its ongoing share ...
Shares of Symbotic Inc. (NASDAQ: SYM) surged in pre-market trading after the company reported better-than-expected fourth-quarter sales results. The company reported quarterly sales of $392.00 million which exceeded the analyst consensus estimate of $306.90 million. Symbotic reported quarterly losses of 8 cents per share, a 20% increase over losses of 10 cents per share from the same period last year, according to data from Benzinga Pro. Keybanc maintained Symbotic with an Overweight and raised the price target from $50 to $63. Symbotic shares gained 22% to $45.32 in pre-market trading Here are some other stocks moving in pre-market trading. Gainers TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) shares rose 65.9% to $0.2878 in pre-market trading. TRACON Pharmaceuticals recently announced license of product development platform for $3 million upfront payment. LQR House Inc. (NASDAQ: LQR) shares surged 62.5% to $0.0980 in pre-market trading. LQR House repurchased 1,476,355 shares in its ongoing share buyback initiative. Mountain Crest Acquisition Corp. IV (NASDAQ: MCAF) shares rose 41.2% to $9.20 in pre-market trading after falling more than 12% on Monday. Marpai, Inc. (NASDAQ: MRAI) rose 27.5% to $1.16 in pre-market trading. Marpai Form 4 filing showed Eitan Yaron bought 100,000 shares at an average price ...
Shares of ReNew Energy Global Plc (NASDAQ: RNW) gained during Monday’s session following strong quarterly sales. ReNew Energy Global posted quarterly sales of $345.00 million, topping market estimates of $258.41 million. ReNew Energy raised its FY24 adjusted EBITDA guidance to INR 62 billion - INR 66 billion. ReNew Energy Global gained 13.6% to $6.74 on Monday. Here are some other stocks moving in today's mid-day session. Gainers Bruush Oral Care Inc. (NASDAQ: BRSH) shares jumped 147.2% to $0.4179. Brüush received Nasdaq notification regarding minimum bid requirements. Cuentas Inc. (NASDAQ: CUEN) shares gained 59% to $1.5098 after reporting a narrower quarterly loss. Altamira Therapeutics Ltd. (NASDAQ: CYTO) jumped 52% to $0.4280. Altamira Therapeutics recently entered into a binding agreement for the sale of a 51% stake in its subsidiary Altamira Medica AG. Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) gained 41.4% to $1.4000. Cardio Diagnostics Holdings announced the publication of its study in the Journal of the American Heart Association (JAHA), an official journal of the American Heart Association. YPF Sociedad Anónima (NYSE: YPF) shares climbed 40.8% to $15.11. Javier Milei‘s victory in Argentina’s presidential election sparked a rally in Argentine ADRs trading on major U.S. stock exchanges. GD Culture Group Limited (NASDAQ: GDC) rose 26.8% to $4.3074. GD Culture Group unveiled its transformative and photorealistic AI-driven digital human technology on TikTok. Blue Star Foods Corp. (NASDAQ: BSFC) shares gained 26.8% to $0.1752 after jumping 18% on Friday. Blue Star Foods recently signed a 2-year bid award purchase agreement with Sysco Corporation. MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) gained 25.3% to $4.2729. MIRA Pharmaceuticals announced exclusive licensing agreement for oral ketamine analog, Ketamir-2. Grupo Financiero Galicia S.A. (NASDAQ: GGAL) rose 25% to $15.63 after gaining 5% on Friday. Transportadora de Gas del Sur S.A. (NYSE: TGS) shares climbed 23.1% to $12.88 after gaining over 4% on Friday. Central Puerto S.A. (NYSE: CEPU) climbed 23.1% to $7.58. Pampa Energía S.A. (NYSE: PAM) gained 23% to $45.60. Transportadora de Gas del Sur S.A. (NYSE: TGS) rose 22.6% to $12.82 after ...
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 500 points on Monday. The Dow traded up 1.67% to 32,959.68 while the NASDAQ rose 1.25% to 12,800.95. The S&P 500 also rose, gaining, 1.23% to 4,167.91. Check This Out: Top 4 Consumer Stocks That Could Blast Off This Quarter Leading and Lagging Sectors Communication services shares jumped by 2.3% on Monday. In trading on Monday, energy shares fell by 0.1%. Top Headline Western Digital Corp (NASDAQ: WDC) reported upbeat first-quarter results and announced a plan to separate its HDD and Flash businesses. Western Digital reported a first-quarter FY23 revenue decline of 26% year-on-year to $2.75 billion, beating the consensus of $2.65 billion. The company clocked an adjusted EPS loss of $(1.76), beating the consensus loss of $(1.90). The company’s board unanimously approved a plan to separate its HDD and Flash businesses. Equities Trading UP Miromatrix Medical Inc. (NASDAQ: MIRO) shares shot up 225% to $3.2858 after United ...
Gainers Miromatrix Medical Inc. (NASDAQ: MIRO) shares climbed 230.7% to $3.3401 after United Therapeutics agreed to acquire the company for $3.25 per share in cash. Eargo, Inc. (NASDAQ: EAR) shares climbed 50.4% to $2.5274 after the company announced it will be taken private by Patient Square Capital. VYNE Therapeutics Inc. (NASDAQ: VYNE) gained 39.9% to $3.1399 after the company announced a private placement of $88 million and data from its Phase 1b trial evaluating once-daily dosing of VYN201 in patients with nonsegmental vitiligo. Conduit Pharmaceuticals Inc. (NASDAQ: CDT) shares gained 27.9% to $1.3042 after falling more than 12% on Friday. HeartCore Enterprises, Inc. (NASDAQ: HTCR) surged 24% to $0.7718. Heartcore Enterprises recently entered into at-market offering agreement for an at-market offering with H.C. Wainwright & Co. ImmunityBio, Inc. (NASDAQ: IBRX) gained 19.4% to $2.9600. The FDA recently accepted ImmunityBio's resubmission of its Biologics License Application for N-803 as complete. Coherus BioSciences, Inc. (NASDAQ: CHRS) shares climbed 16.8% to $3.0850. Coherus and Junshi Biosciences reported FDA approval of LOQTORZI in all lines of treatment for recurrent or metastatic nasopharyngeal carcinoma. Aemetis, Inc. (NASDAQ: AMTX) gained 16.5% to $5.02. Aemetis received $150 million biodiesel supply allocation from India oil marketing companies. JinkoSolar Holding Co., Ltd. (NYSE: JKS) surged 16% to $30.01 following better-than-expected quarterly results. Akerna Corp. (NASDAQ: KERN) jumped 16% to $0.3550. MeiraGTx Holdings plc (NASDAQ: MGTX) rose 16% to $4.29. MeiraGTx announced a $30 million strategic investment from Sanofi via purchase of 4 million shares at $7.50 per share. Motus GI ...